knowledge -WSS

knowledge

author：entertainment 2025-10-02 18:50:00 - browse：557

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Europe is fastest

focus

Wikipedia

WSS

What AstraZeneca

'Weather

US jobless claims fall again as labor market continues to flash strength

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Extensive review finds private equity owners jack up cost of care

What AstraZeneca

leisure time

knowledge

explore

New air purifier tech could be key to improving indoor air quality

Doctors in states that ban abortion can still help patients

New air purifier tech could be key to improving indoor air quality

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Continuity nursing helped my family in our darkest PICU moments

Mystery swirls around US soldier who entered North Korea days ago, officials say

United colonoscopy coverage change 'may cost lives,' doctors say

Doctors increasingly discourage vaping amid mounting health concerns

Bright Health sells Medicare Advantage business to Molina

Adidas to release second batch of Yeezy sneakers after breakup with Ye

focus

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

'Weather

HCA says smaller share of spending going to labor

Adidas to release second batch of Yeezy sneakers after breakup with Ye

Adidas to release second batch of Yeezy sneakers after breakup with Ye

Judge denies Trump's request for new trial in E. Jean Carroll case

focus

Wikipedia

knowledge

leisure time